We are live on ! Find out more
BTCY

Biotricity, Inc. Common Stock

Delisted

BTCY was delisted on the 2nd of August, 2024.

29 hedge funds and large institutions have $1.19M invested in Biotricity, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 4

0% more funds holding

Funds holding: 2929 (0)

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

42% less capital invested

Capital invested by funds: $2.05M → $1.19M (-$869K)

Holders
29
Holders Change
Holders Change %
0%
% of All Funds
0.48%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
7
Reduced
4
Closed
4
Calls
Puts
Net Calls
Net Calls Change

BTCY Hedge Fund Activity: Q4 2022 in Review

29 of the 6,103 institutional investors tracked by Wall St. Rank reported a position in Biotricity, Inc. Common Stock (BTCY) for Q4 2022, worth a combined $1.19M — down 42% from $2.05M a quarter earlier.

Fund positioning in BTCY was balanced in Q4 2022: 4 funds opened new positions, 4 closed out, 7 added to existing stakes and 4 trimmed.

The largest buyer was AE Wealth Management, opening a new position worth an estimated $46.1K. The largest seller was Citadel Advisors, exiting entirely with an estimated $19K sold.

  • 29 institutional investors held Biotricity, Inc. Common Stock (BTCY) as of Q4 2022, unchanged from Q3 2022.
  • Funds reported $1.19M of Biotricity, Inc. Common Stock stock for Q4 2022, down 42% quarter-over-quarter.
  • 4 funds opened new Biotricity, Inc. Common Stock positions in Q4 2022 and 4 closed out, a net change of 0 holders.
  • The largest Biotricity, Inc. Common Stock buyer in Q4 2022 was AE Wealth Management, an estimated $46.1K added.
  • The largest Biotricity, Inc. Common Stock seller in Q4 2022 was Citadel Advisors, an estimated $19K sold.

Based on aggregated 13F filings for Q4 2022.